Clarivate(CLVT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [15] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [15] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [15] - Free cash flow for the full year reached $365 million, reflecting a 2% growth over the prior year [19] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [10] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [12] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [12] Market Data and Key Metrics Changes - The company reported stable revenue retention rates of 93% and expects organic annual contract value growth of 2%-3% for 2026 [13][21] - The anticipated decline in revenue due to strategic disposals is expected to be approximately $100 million, with organic recurring revenue mix improving to between 88% and 90% [21][23] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance emphasis on the A&G and IP markets and strengthen its balance sheet [5][49] - The AI strategy is centered on leveraging proprietary data and domain expertise to enhance product offerings, with 97% of revenue derived from proprietary assets [6][42] - The company aims to maximize shareholder value through portfolio simplification and disciplined capital allocation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued improvement in key financial metrics and organic growth acceleration supported by AI innovation [14][13] - The company acknowledges market concerns regarding AI disruption but believes its proprietary business model provides a significant competitive advantage [5][6] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to create shareholder value and allow for a more focused operational execution across A&G and IP segments [5][49] - The company plans to continue investing in product innovation while also focusing on cost efficiencies to improve capital spending [27] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management confirmed that the subscription model is evolving, with a focus on upselling AI innovations and transitioning to more subscription-based products [32][33] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with a significant portion from information services and enterprise software [42] Question: Considerations for selling Life Sciences and Healthcare business - The decision was based on the goal of creating shareholder value and focusing on the A&G and IP segments, which have synergies [48][49] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the two segments, which can enhance innovation and operational execution [53][56] Question: Returning the IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing strong assets and a focus on innovation and execution [60][62] Question: Capital allocation priorities - Management indicated a focus on deleveraging while also considering stock buybacks, emphasizing the attractive free cash flow yield [68][70] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [72][75]